Hoosier Oncology Group is very pleased to announce that Christopher A. Fausel, PharmD, MHA, BCOP, was appointed Chairman of the Board of Directors on July 31, 2013.

Dr. Fausel is the Clinical Manager of Oncology Pharmacy at the Indiana University Simon Cancer Center (IUSCC) in Indianapolis. He graduated from Albany College of Pharmacy with a BS in Pharmacy in 1993, a PharmD in 1996, and completed residency training at the Stratton VA Medical Center in Albany, N.Y. In 2013, he received a Master of Health Administration degree from Simmons College in Boston, Mass. He oversees the clinical and dispensing pharmacy services at the IUSCC ambulatory infusion center and six satellite infusion clinics.

Dr. Fausel holds academic appointments in the Department of Medicine at the Indiana University School of Medicine, Purdue University School of Pharmacy and Pharmacal Sciences, and Butler University College of Pharmacy. He is the founding Residency Program Director for the PGY2 Oncology Pharmacy Residency at Indiana University Health. In addition to his role as Chairman of the Hoosier Oncology Group, he also serves on the Indiana University Purdue University at Indianapolis IRB and the Indiana University Simon Cancer Center Scientific Review Committee. He is a long-standing member of ASHP, ASCO, and HOPA.

We look forward to continued growth and innovation under his leadership!

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,400 patients have participated in Hoosier Cancer Research Network clinical trials.